XM does not provide services to residents of the United States of America.
G
G

Givaudan

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Swiss stocks - Factors to watch on June 11

Swiss stocks - Factors to watch on June 11 ZURICH/GDANSK, June 11(Reuters) - Here are some of the main factors that may affect Swiss stocks on Tuesday: SNB SNBN.S The race to appoint the new Swiss central bank chief is nearing an end. The Swiss National Bank's supervisory board is in the final stages of deciding its candidate to replace outgoing Chairman Thomas Jordan, people familiar with the matter have told Reuters.
G
H
S
S

Dsm-firmenich sees boost as weight-loss drugs spur healthier choices

UPDATE 1-Dsm-firmenich sees boost as weight-loss drugs spur healthier choices Weight-loss drugs seen boosting demand for dietary supplements Preventive healthcare could raise interest in new ingredients Updates paragraph 12 to make it clear company is reviewing options including sale or IPO for Animal Nutrition division By Dimitri Rhodes and Matteo Allievi June 10 (Reuters) - The soaring popularity of weight-loss drugs are likely to spur demand for dietary supplements and healthier food formulat
G
K
L
S

Dsm-firmenich sees boost as weight-loss drugs spur healthier choices

Dsm-firmenich sees boost as weight-loss drugs spur healthier choices Weight-loss drugs seen boosting demand for dietary supplements Preventive healthcare could raise interest in new ingredients By Dimitri Rhodes and Matteo Allievi June 10 (Reuters) - The soaring popularity of weight-loss drugs are likely to spur demand for dietary supplements and healthier food formulations, creating growth opportunities for dsm-firmenich, the CEO of the flavours to nutrition company told Reuters.
G
K
L
S

Barclays ups Givaudan to 'equal weight' on better outlook

BUZZ-Barclays ups Givaudan to 'equal weight' on better outlook ** Barclays raises Swiss fragrance maker Givaudan GIVN.S to "equal weight" from "underweight" and hikes its PT by 14% to 4,000 Swiss francs ($4,462), pointing to a better than feared outlook for Fine Fragrances unit ** It says Givaudan's premium valuation reflects strong underlying momentum and expects an 2024 and 2025 adj.
G

Aviva, DCC, Puig Brands

EUROPE RESEARCH ROUNDUP-Aviva, DCC, Puig Brands June 10 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Aviva, DCC and Puig Brands on Monday. HIGHLIGHTS * Aviva AV.L : JP Morgan removes stock from its analyst focus list * Bellway Plc BWY.L : Citigroup raises target price to 3151p from 3033p * Computacenter Plc CCC.L : Peel Hunt raises to buy from add * DCC DCC.L : Jefferies raises target price to 7600p from 7400p * Puig Brands SA P
A
A
A
A
B
C
C
D
D
D
G
H
N
P
R
U
V
A
A
B
L
Z

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.